Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

A8236

Sigma-Aldrich

AN-9

≥95% (HPLC)

Synonyme(s) :

Pivaloyloxymethyl butyrate, Pivanex

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H18O4
Numéro CAS:
122110-53-6
Poids moléculaire :
202.25
Numéro MDL:
MFCD00209896
Code UNSPSC :
12352200
ID de substance PubChem :
329770954
Nomenclature NACRES :
NA.77

Pureté

≥95% (HPLC)

Forme

oil

Couleur

colorless to slightly yellow

Solubilité

DMSO: ≥10 mg/mL

Température de stockage

−20°C

Chaîne SMILES 

CCCC(=O)OCOC(=O)C(C)(C)C

InChI

1S/C10H18O4/c1-5-6-8(11)13-7-14-9(12)10(2,3)4/h5-7H2,1-4H3

Clé InChI

GYKLFBYWXZYSOW-UHFFFAOYSA-N

Application

AN-9 is a HDAC inhibitor with antimetastatic and antiangiogenic properties. These anticancer activities are thought to occur by reducing vascularization and the expression of bFGF and HIF-1α.

Actions biochimiques/physiologiques

HDAC Inhibitor tested as an anti-cancer drug; butyric acid pro-drug

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

nwg

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Suzanne M Cutts et al.
Oncology research, 15(4), 199-213 (2007-09-08)
The anticancer drug Adriamycin is widely used in cancer chemotherapy and is classified as a topoisomerase II inhibitor. However, in the presence of formaldehyde, Adriamycin also forms high levels of DNA adducts. In this study, a new series of butyric
S M Cutts et al.
Cancer research, 61(22), 8194-8202 (2001-11-24)
The interaction of Adriamycin and pivaloyloxymethyl butyrate (AN-9) was investigated in IMR-32 neuroblastoma and MCF-7 breast adenocarcinoma cells. Adriamycin is a widely used anticancer drug, whereas AN-9 is an anticancer agent presently undergoing Phase II clinical trials. The anticancer activity
Belinda S Parker et al.
Cancer biology & therapy, 2(3), 259-263 (2003-07-25)
In addition to its action as a topoisomerase II poison, mitoxantrone is activated by formaldehyde to bind DNA, forming DNA-adducts specifically at 5'CpG and CpA sequences, with an enhancement of adducts at methylated CpG sites. The butyric acid prodrug, AN-9
A Aviram et al.
International journal of cancer, 56(6), 906-909 (1994-03-15)
A butyric acid pro-drug, pivaloyloxymethyl butyrate, AN-9, developed in our laboratory, was previously shown to act as a differentiation-inducing and an anti-cancer agent. In this study we have shown that both AN-9 and butyric acid caused a transient hyperacetylation of
Nataly Tarasenko et al.
Clinical & experimental metastasis, 25(7), 703-716 (2008-05-29)
Histone deacetylase inhibitory prodrugs that are metabolized to butyric acid and formaldehyde possess antineoplastic properties and low toxicity. We sought to characterize the antiangiogenic and antimetastatic activities of two lead prodrugs, pivaloyloxymethyl butyrate (AN-9) and butyroyloxymethyl-diethyl phosphate (AN-7) in murine
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique